Mentions in press and media 3
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jan 14, 2026 | Lahjavida Bio Accepted to Present Tumor-Targeted Small-Molecule Drug Delivery Platform at AACR Annual Meeting 2026 | COLORADO SPRINGS, CO, UNITED STATES, January 14, 2026 /EINPresswire.com/ -- Lahjavida Bio, a biotechnology company pioneering a new class of tumor-targeted small-molecule cancer therapies, today announced that an abstract describing its pro... |
| Oct 28, 2025 | Lahjavida Appoints Veteran Oncology Drug Developer Dr. Paul Algate as Senior Vice President of Research and Development | COLORADO SPRINGS, CO, UNITED STATES, October 28, 2025 /EINPresswire.com/ -- Lahjavida, a biotechnology company advancing a novel class of small-molecule dye–drug conjugates (DDCs) that bring antibody-drug conjugate (ADC)-level precision to ... |
Reviews 0
FAQ about Lahjavida Bio
What has the press written about Lahjavida Bio?
Parsers VC has collected 3 articles mentioning Lahjavida Bio, among them “Lahjavida Bio Accepted to Present Tumor-Targeted Small-Molecule Drug Delivery Platform at AACR Annual Meeting 2026” (Jan 14, 2026) and “Lahjavida Appoints Veteran Oncology Drug Developer Dr. Paul Algate as Senior Vice President of Research and Development” (Oct 28, 2025).
Is Lahjavida Bio still active?
Yes, Lahjavida Bio is active; its latest activity on Parsers VC dates from Feb 13, 2026.